Cargando…
PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429769/ http://dx.doi.org/10.1097/01.HS9.0000975296.46536.6a |
| _version_ | 1785090794548363264 |
|---|---|
| author | Weisel, Katja Hungria, Vania Quach, Hang Yoon, Sung-Soo Rodríguez-Otero, Paula Kroog, Glenn Sinha, Arijit Boyapati, Anita Lyon, Charlotte Lorenc, Karen Rodriguez Inocencio, Timothy Harnett, James Chi, Lei Moore, Vygngley Voorhees, Peter |
| author_facet | Weisel, Katja Hungria, Vania Quach, Hang Yoon, Sung-Soo Rodríguez-Otero, Paula Kroog, Glenn Sinha, Arijit Boyapati, Anita Lyon, Charlotte Lorenc, Karen Rodriguez Inocencio, Timothy Harnett, James Chi, Lei Moore, Vygngley Voorhees, Peter |
| author_sort | Weisel, Katja |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429769 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297692023-08-17 PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Weisel, Katja Hungria, Vania Quach, Hang Yoon, Sung-Soo Rodríguez-Otero, Paula Kroog, Glenn Sinha, Arijit Boyapati, Anita Lyon, Charlotte Lorenc, Karen Rodriguez Inocencio, Timothy Harnett, James Chi, Lei Moore, Vygngley Voorhees, Peter Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429769/ http://dx.doi.org/10.1097/01.HS9.0000975296.46536.6a Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Weisel, Katja Hungria, Vania Quach, Hang Yoon, Sung-Soo Rodríguez-Otero, Paula Kroog, Glenn Sinha, Arijit Boyapati, Anita Lyon, Charlotte Lorenc, Karen Rodriguez Inocencio, Timothy Harnett, James Chi, Lei Moore, Vygngley Voorhees, Peter PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_full | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_fullStr | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_full_unstemmed | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_short | PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
| title_sort | pb2133: trial in progress: linker-mm3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (epd) in relapsed/refractory multiple myeloma (rrmm) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429769/ http://dx.doi.org/10.1097/01.HS9.0000975296.46536.6a |
| work_keys_str_mv | AT weiselkatja pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT hungriavania pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT quachhang pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT yoonsungsoo pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT rodriguezoteropaula pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT kroogglenn pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT sinhaarijit pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT boyapatianita pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT lyoncharlotte pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT lorenckarenrodriguez pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT inocenciotimothy pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT harnettjames pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT chilei pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT moorevygngley pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm AT voorheespeter pb2133trialinprogresslinkermm3aphase3openlabelrandomizedstudyoflinvoseltamabversuselotuzumabpomalidomideanddexamethasoneepdinrelapsedrefractorymultiplemyelomarrmm |